WP 1097
Alternative Names: WP-1097Latest Information Update: 09 Aug 2023
At a glance
- Originator Moleculin Biotech
- Class Antivirals; Small molecules
- Mechanism of Action Coronavirus spike glycoprotein modulators; Glycolysis inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical COVID 2019 infections; Dengue; HIV infections; Viral haemorrhagic fevers; Zika virus infection
Most Recent Events
- 09 Aug 2023 Preclinical trials in Viral haemorrhagic fevers in USA (unspecified route) (Moleculin Biotech Pipeline, Aug 2023)
- 06 Oct 2020 Moleculin biotech enters in a research collaboration with Rega Institute for Medical Research for WP 1097, prior to October 2020
- 06 Oct 2020 Preclinical trials in COVID-2019 infections in USA (Unspecified)